Glaxosmithkline Pharmaceuticals Ltd.
GLAXO · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,316.35.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%49.1%
- ✓Low debt (D/E < 0.5)0.01x
- ✓Positive free cash flow
- ✕Revenue growth > 10%2%
- ✓Earnings growing6%
- ✓Net margin ≥ 10%27.1%
- ✓Current ratio > 1.52.03
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 12.33
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (49.1%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (27.1%).
- •Financially solid — Altman Z 12.33.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Well off its 52-week high — possible mean-reversion.
Threats
- •Trades ~23% above our estimated fair value.
About Glaxosmithkline Pharmaceuticals Ltd.
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused b
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.